These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35815768)

  • 21. The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
    Basyigit S; Kefeli A; Sapmaz F; Yeniova AO; Asilturk Z; Hokkaomeroglu M; Uzman M; Nazligul Y
    Bosn J Basic Med Sci; 2015 Oct; 15(4):50-4. PubMed ID: 26614852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New simplified regimen for Helicobacter pylori eradication achieves high effectiveness. Prospective study in a private clinic in Lima, Peru].
    Barreda Costa CS; Barriga Briceño JA; Piccini Larco JR
    Rev Gastroenterol Peru; 2017; 37(3):225-230. PubMed ID: 29093585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events].
    Hinostroza Morales D; Díaz Ferrer J
    Rev Gastroenterol Peru; 2014; 34(4):315-20. PubMed ID: 25594755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.
    Chang YW; Shin GY; Kim JW; Moon JC; Chang EJ; Oh CH; Jang JY
    Dig Dis Sci; 2022 Apr; 67(4):1222-1230. PubMed ID: 33755825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
    Valle Muñoz J; Muñoz Gómez P; Sierra Bernal C; de Andrés E; Gómez Hernando C; Gómez Rodríguez R
    Rev Esp Enferm Dig; 2019 Sep; 111(9):655-661. PubMed ID: 31345044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tailored eradication
    Choi YI; Chung JW; Park DK; Kim KO; Kwon KA; Kim YJ; Seo JY
    World J Gastroenterol; 2019 Dec; 25(46):6743-6751. PubMed ID: 31857776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
    Yu L; Luo L; Long X; Liang X; Ji Y; Graham DY; Lu H
    Helicobacter; 2019 Aug; 24(4):e12596. PubMed ID: 31111580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Several issues on amoxicillin in
    Yang GB
    Zhonghua Yi Xue Za Zhi; 2020 Aug; 100(30):2340-2342. PubMed ID: 32791808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
    Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
    Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
    Zhou Y; Ye Z; Wang Y; Zhang Y; Tang Z; Yan W; Jiang Y; Huang Y
    Helicobacter; 2020 Apr; 25(2):e12679. PubMed ID: 31958193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP; Perez-Aisa A; Rodrigo L; Molina-Infante J; Modolell I; Bermejo F; Castro-Fernández M; Antón R; Sacristán B; Cosme A; Barrio J; Harb Y; Gonzalez-Barcenas M; Fernandez-Bermejo M; Algaba A; Marín AC; McNicholl AG;
    Dig Dis Sci; 2014 Feb; 59(2):383-9. PubMed ID: 24126798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow].
    Bordin DS; Voynovan IN; Embutnieks YV; Nyssen OP; Megraud F; O Morain C; Perez-Gisbert J
    Ter Arkh; 2020 Apr; 92(2):12-18. PubMed ID: 32598712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
    Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reflux masquerader: acute Helicobacter pylori infection in neonates and infants.
    Frem JC; Gold BD; Shehata BM; Cole CR
    J Pediatr Gastroenterol Nutr; 2008 May; 46(5):589-92. PubMed ID: 18493216
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eradication Rate of
    Liu RP; Romero R; Sarosiek J; Dodoo C; Dwivedi AK; Zuckerman MJ
    South Med J; 2018 Jan; 111(1):51-55. PubMed ID: 29298370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bismuth-based therapies for the first step eradication of Helicobacter pylori.
    Sezgin O; Altintaş E; Uçbilek E; Tataroğlu C
    Turk J Gastroenterol; 2006 Jun; 17(2):90-3. PubMed ID: 16830288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helicobacter pylori eradication therapy.
    Suzuki H; Nishizawa T; Hibi T
    Future Microbiol; 2010 Apr; 5(4):639-48. PubMed ID: 20353303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection].
    Campillo A; Ostiz M; Amorena E; Kutz M; La Iglesia M
    Med Clin (Barc); 2016 Sep; 147(5):199-201. PubMed ID: 27374029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.